DISCUSSION
thrombosis, bleeding, death
THROMBOSIS, EVENTS, BLEEDING
In the Bioflow-DAPT Study, we found that for patients at high risk for bleeding and received 1 month of DAPT after PCI, the biodegradable-polymer sirolimus-eluting stent was noninferior to the durable-polymer zotarolimus-eluting stent at 1 year with respect to the primary outcome of death from cardiac causes, MI, or stent thrombosis.This is the first study to show that clinical outcomes after biodegradable-polymer sirolimus-eluting stents did not differ compared with durable-polymer zotarolimus-eluting stents in patients at high risk for bleeding undergoing 1 month of DAPT after intervention. The current study builds on previous evidence.The current study had similar inclusion and exclusion criteria compared with previous investigations assessing different stents in patients at high risk for bleeding.The most important limitation of the trial is that the incidences of outcome events at 1 year were lower than expected on the basis of data from the Onyx ONE trial.